Program Type: New England CEPAC

Retinitis Pigmentosa

Apr 2025 | Assessment

Interventions of Interest For questions please contact Madeline Booth, Program Manager, mbooth@icer.org. View the Key Stakeholder List.

Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Nov 2024 | Assessment

Interventions of Interest Post-transplant lymphoproliferative disease (PTLD) is a rare, serious, often fatal complication of solid organ transplant (SOT) and allogeneic hematopoietic stem cell transplant (HCST), with only several hundred cases per year reported in the US. The majority of cases of PTLD are associated with the acquisition or reactivation of Epstein-Barr virus (EBV) post-transplant […]

Post-Traumatic Stress Disorder

May 2024 | Assessment

Interventions of Interest Independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits for MDMA-AP compared to short-term trauma-focused psychotherapies. Click here for “Five Fast Facts on ICER and our PTSD Report.” For questions or to request a Spanish translated Report-at-a-Glance or ICER Snapshot for this assessment, please contact info@icer.org. […]

Schizophrenia

Feb 2024 | Assessment

Interventions of Interest: The independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits for KarXT compared to generically available aripiprazole. If long-term data confirm KarXT’s benefits and lack of weight gain, it would achieve common thresholds for cost-effectiveness if priced between $16,000 to $20,000 per year. Final Documents […]